Last close · 16 Oct 2026
Rs 31.99 +0.22%
Annual · FY2016 – FY2026
Liven Pharma Limited (LIVEN) financial ratios
Liven Pharma Limited earned a net margin of -29.4% in FY2026 (Pharmaceuticals median 9.4%). Return on equity was -3.8%, compared with a sector median of 21.7%. The current ratio stood at 2.63× and debt was 3.4% of equity. Cash took about 203 days to cycle through receivables, inventory and payables.
FY2026 vs the Pharmaceuticals median
- Gross margin
- 25.2%
- Sector median 37.0%
- Operating margin
- -59.0%
- Sector median 17.3%
- Net margin
- -29.4%
- Sector median 9.4%
- Return on equity (ROE)
- -3.8%
- Sector median 21.7%
- Return on assets (ROA)
- -3.1%
- Sector median 11.7%
- Current ratio
- 2.63×
- Sector median 1.79×
- Debt to equity
- 3.4%
- Sector median 5.8%
- Asset turnover
- 0.10×
- Sector median 1.26×
Median of the 14 companies in the sector with the figure for their latest fiscal year.
| Rs mn | FY2026 Jul 2025 – Jun 2026 | FY2025 * Jul 2024 – Jun 2025 | FY2024 * Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||
| Gross margin | 25.2% | 14.1% | — | — | — | ||||||
| EBITDA margin | (29.8%) | (363.1%) | — | — | — | ||||||
| Operating margin | (59.0%) | (384.9%) | — | — | — | ||||||
| Pre-tax margin | (62.7%) | (386.7%) | — | — | — | ||||||
| Net margin | (29.4%) | (459.2%) | — | — | — | ||||||
| Returns | |||||||||||
| Return on equity (ROE) | (3.8%) | (233.8%) | — | — | — | ||||||
| Return on assets (ROA) | (3.1%) | (124.0%) | (8.9%) | (8.9%) | (9.4%) | ||||||
| Liquidity | |||||||||||
| Current ratio | 2.63× | 1.64× | 0.00× | 0.00× | 0.00× | ||||||
| Quick ratio | 1.80× | 0.27× | — | — | — | ||||||
| Leverage | |||||||||||
| Debt to equity | 3.4% | 5.5% | — | — | — | ||||||
| Debt to capital | 3.3% | 5.2% | 227.8% | 206.6% | 188.2% | ||||||
| Debt to assets | 2.7% | 4.2% | 199.2% | 180.7% | 162.8% | ||||||
| Assets to equity | 1.26× | 1.89× | — | — | — | ||||||
| Efficiency | |||||||||||
| Asset turnover | 0.10× | 0.27× | 0.00× | 0.00× | 0.00× | ||||||
| Receivable days days | 37 | — | — | — | — | ||||||
| Inventory days days | 500 | — | — | — | — | ||||||
| Payable days days | 332 | 103 | — | — | — | ||||||
| Cash conversion cycle days | 203 | — | — | — | — | ||||||
Ratios as reported for each fiscal year; returns are on average equity / assets. Debt ratios are percentages; turnover in times; working-capital measures in days.
LIVEN: frequently asked questions
What is LIVEN's EPS?
Liven Pharma Limited reported basic earnings per share of Rs -0.28 for FY2026 (Jul 2025 – Jun 2026).
Does LIVEN pay dividends?
Liven Pharma Limited did not declare a cash dividend for FY2026.
What was LIVEN's revenue and profit in FY2026?
Liven Pharma Limited reported revenue of Rs 105.8 mn and profit attributable to shareholders of -Rs 31.1 mn for FY2026 (Jul 2025 – Jun 2026).
What is LIVEN's book value per share?
Liven Pharma Limited's book value per share was Rs 8.72 at the end of FY2026. The shares trade at 3.67× book value.
Information only, not investment advice.